Advances of neuroimaging in chemotherapy related cognitive impairment (CRCI) of patients with breast cancer

Yao, Senbang; Zhang, Qianqian; Xiao, Yao; Zhang, Xiuqing; Pang, Lulian; Yu, Sheng; Huang, Cheng

doi:10.1007/s10549-023-07005-y

Cited by 5 publications

(3 citation statements)

References 50 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The development of MRI technology has made it possible to explore the structural and functional abnormalities of brain regions, as well as structural and functional connectivity between different brain regions in cancer patients before and after chemotherapy (Sim o et al, 2013). Previous neuroimaging studies had revealed abnormal brain activities, impaired white matter integrity, and decreased grey matter in cancer patients who underwent chemotherapy, and these abnormalities were related with the degree of cognitive decline of patients (Cheung & Chan, 2013;Sim o et al, 2013;Yao et al, 2023).…”

Section: Discussionmentioning

confidence: 99%

Effects of D‐CAG chemotherapy regimen on cognitive function in patients with acute myeloid leukaemia: A resting‐state functional magnetic resonance imaging study

Hu,

Su,

Liu

et al. 2023

Eur J of Neuroscience

View full text Add to dashboard Cite

Post‐chemotherapy cognitive impairment, also known as ‘chemobrain’, is a common neurotoxic complication induced by chemotherapy, which has been reported in many cancer survivors who have undergone chemotherapy. In this study, we aimed to explore the effects of D‐neneneba dicitabine, C‐nenenebb cytarabine, A‐aclamycin, G‐granulocyte colony‐stimulating factor (D‐CAG) chemotherapy on cognitive function in patients with acute myeloid leukaemia (AML) and its possible central mechanisms. Twenty patients with AML and 25 matched healthy controls (HC) were enrolled in this study. The cognitive function of patients before and after D‐CAG chemotherapy was evaluated by the Functional Assessment of Cancer Therapy‐Cognitive Function (FACT‐Cog). The resting‐state functional magnetic resonance imaging data were collected from all patients before and after chemotherapy intervention, as well as HC. Then, resting‐state functional magnetic resonance imaging data were preprocessed using DPABI software package and regional homogeneity (ReHo) values of brain regions were calculated. Finally, ReHo values between groups were compared by Resting‐State fMRI Data Analysis software package with t‐tests and Alphasim method was performed for multiple comparison correction. Moreover, associations between ReHo values of altered brain regions and the scores of FACT‐Cog were analysed by Pearson correlation. The total FACT‐Cog scores and four factor scores of AML patients increased significantly after treatment. ReHo values showed no significant changes in patients before treatment when compared with HC. Compared with HC, ReHo values of the right middle frontal gyrus, inferior frontal gyrus (opercular part), middle occipital gyrus, and left praecuneus decreased significantly, while ReHo values of the left inferior temporal gyrus, right middle temporal gyrus, and hippocampus increased significantly in patients after treatment. Compared with patients before treatment, ReHo values decreased significantly in the right middle frontal gyrus, inferior frontal gyrus (opercular part), and middle and inferior occipital gyri of patients after treatment. In addition, ReHo values of the right inferior frontal gyrus (opercular part) were negatively correlated with the total scores of FACT‐Cog and factor scores of perceived cognitive impairment in patients after treatment. There were also negative correlations between ReHo values of the right middle frontal gyrus and perceived cognitive impairment scores. The present study confirmed that D‐CAG chemotherapy might cause impaired subjective self‐reported cognitive functioning in AML patients, which might be related to the decreased function of certain regions in the right prefrontal lobe. These findings provided further understanding of the mechanisms involved in post‐chemotherapy cognitive impairment and would help develop new therapeutic strategies for ‘chemobrain’ in AML patients.

show abstract

Section: Discussionmentioning

confidence: 99%

Effects of D‐CAG chemotherapy regimen on cognitive function in patients with acute myeloid leukaemia: A resting‐state functional magnetic resonance imaging study

Hu,

Su,

Liu

et al. 2023

Eur J of Neuroscience

View full text Add to dashboard Cite

show abstract

“…The bulk of our understanding of chemotherapy-associated CRCI stems from studies of cognitive impairment in BC survivors during and after chemotherapy treatment (summarized in Table 1 ) ( 19 , 29 , 64 , 80 – 82 ). BC patients after chemotherapy treatment report deficits in cognitive domains consisting of executive function, working memory, attention, concentration, processing speed, cognitive flexibility, visual and verbal memory ( 83 ).…”

Section: Cancer Related Cognitive Impairmentmentioning

confidence: 99%

“…Mechanistically, numerous studies have implicated systemic inflammation as a major contributor to chemotherapy-associated CRCI in BC patients. Chemotherapy associated inflammation is a potential significant contributor to CRCI; a thorough review of this subject is beyond the scope of the paper but has been well described in recent years ( 15 , 80 , 81 ). Chemotherapy agents have been reported to elevate multiple pro-inflammatory markers including interlukin-6 (IL-6), IL-1 beta (IL-1β), IL-5, IL-10, reactive oxygen species (ROS), IL-8, interferon gamma (IFN-α), IL-12, IL-17, and tumor necrosis factor alpha (TNF-α) ( 15 , 82 ).…”

Section: Cancer Related Cognitive Impairmentmentioning

confidence: 99%

Cancer related cognitive impairment: a downside of cancer treatment

Demos-Davies,

Lawrence,

Seelig

2024

Front. Oncol.

View full text Add to dashboard Cite

Cancer treatment is associated with long lasting cognitive impairment in cancer survivors. This cognitive impairment is often termed cancer related cognitive impairment (CRCI). Cancer survivors treated for tumors outside the central nervous system are increasingly diagnosed with CRCI. The development of strategies to mitigate the negative effects of cancer treatment on the brain are crucial. Although neuroimaging research has proposed several candidate mechanisms, the pathogenic underpinnings of CRCI remain uncertain. As such, preventative and treatment strategies have not been identified. To fill these gaps, animal models play a vital role in isolating underlying contributing mechanisms that promote CRCI and in testing new therapeutic approaches.

show abstract

Structural brain changes and associated self-perceived cognitive deficits in chemotherapy-exposed patients with breast cancer: a longitudinal T1 and DTI study

Jung,

Chun,

Kim

2024

Curr Psychol

View full text Add to dashboard Cite

Advances of neuroimaging in chemotherapy related cognitive impairment (CRCI) of patients with breast cancer

Cited by 5 publications

References 50 publications

Effects of D‐CAG chemotherapy regimen on cognitive function in patients with acute myeloid leukaemia: A resting‐state functional magnetic resonance imaging study

Effects of D‐CAG chemotherapy regimen on cognitive function in patients with acute myeloid leukaemia: A resting‐state functional magnetic resonance imaging study

Cancer related cognitive impairment: a downside of cancer treatment

Structural brain changes and associated self-perceived cognitive deficits in chemotherapy-exposed patients with breast cancer: a longitudinal T1 and DTI study

Contact Info

Product

Resources

About